Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results

Jorge E. Cortes, B. Douglas Smith, Eunice S. Wang, Akil Merchant, Vivian G. Oehler, Martha Arellano, Daniel J. DeAngelo, Daniel A. Pollyea, Mikkael A. Sekeres, Tadeusz Robak, Weidong Wendy Ma, Mirjana Zeremski, M. Naveed Shaik, A. Douglas Laird, Ashleigh O'Connell, Geoffrey Chan, Mark A. Schroeder

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

Glasdegib is a Hedgehog pathway inhibitor. This ongoing, open-label, phase 2 study (NCT01546038) evaluated glasdegib plus cytarabine/daunorubicin in patients with untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). Patients received glasdegib 100 mg orally, once daily in continuous 28-day cycles from day −3, with intravenous cytarabine 100 mg/m2 on days 1-7 and daunorubicin 60 mg/m2 on days 1-3. Patients in remission then received consolidation therapy (2-4 cycles of cytarabine 1 g/m2 twice daily on days 1, 3, 5 of each cycle), followed by maintenance glasdegib (maximum 6 cycles). Primary endpoint was complete remission (CR) in patients aged ≥55 years. Secondary endpoints included overall survival (OS), safety and outcome by mutational status. Patients had a median (range) age of 64.0 (27-75) years, 60.0% were male, and 84.5% were white. In 69 evaluable patients, 46.4% (80% confidence interval [CI]: 38.7-54.1) achieved investigator-reported CR. Among patients ≥55 years old (n = 60), 40.0% (80% CI 31.9-48.1) achieved CR. Among all 69 patients, median OS was 14.9 (80% CI 13.4-19.3) months, with 12-month survival probability 66.6% (80% CI 58.5-73.4). The most common treatment-related adverse events (≥50% patients) were diarrhea and nausea. There were no significant associations between mutational status (12 genes) and clinical response, suggesting potential benefit across diverse molecular profiles. Glasdegib plus cytarabine/daunorubicin was well tolerated and associated with clinical activity in patients with untreated AML or high-risk MDS. A randomized phase 3 trial of glasdegib in combination with chemotherapy (7 + 3 schedule) is ongoing.

Original languageEnglish (US)
Pages (from-to)1301-1310
Number of pages10
JournalAmerican Journal of Hematology
Volume93
Issue number11
DOIs
StatePublished - Nov 2018

    Fingerprint

ASJC Scopus subject areas

  • Hematology

Cite this

Cortes, J. E., Douglas Smith, B., Wang, E. S., Merchant, A., Oehler, V. G., Arellano, M., DeAngelo, D. J., Pollyea, D. A., Sekeres, M. A., Robak, T., Ma, W. W., Zeremski, M., Naveed Shaik, M., Douglas Laird, A., O'Connell, A., Chan, G., & Schroeder, M. A. (2018). Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. American Journal of Hematology, 93(11), 1301-1310. https://doi.org/10.1002/ajh.25238